{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T07:15:32Z","timestamp":1775200532735,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-22916-0","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:34:10Z","timestamp":1760427250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PCSK9 inhibitors in the management of hypercholesterolaemia after heart transplantation in the UK, a single centre observational study"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7563-7346","authenticated-orcid":false,"given":"Waqas","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2338-9245","authenticated-orcid":false,"given":"Tina","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Neves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charis","family":"Browne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3102-9355","authenticated-orcid":false,"given":"Mahmud","family":"Tawil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0818-3919","authenticated-orcid":false,"given":"Haifa","family":"Lyster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Owais","family":"Dar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"1","key":"22916_CR1","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/J.JACC.2016.04.033","volume":"68","author":"S Chih","year":"2016","unstructured":"Chih, S., Chong, A. Y., Mielniczuk, L. M., Bhatt, D. L. & Beanlands, R. S. B. Allograft vasculopathy: the achilles\u2019 heel of heart transplantation. J. Am. Coll. Cardiol. 68 (1), 80\u201391. https:\/\/doi.org\/10.1016\/J.JACC.2016.04.033 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"8","key":"22916_CR2","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1161\/ATVBAHA.114.302818","volume":"34","author":"JS Pober","year":"2014","unstructured":"Pober, J. S., Jane-Wit, D., Qin, L. & Tellides, G. Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy. Arterioscler. Thromb. Vasc Biol. 34 (8), 1609\u20131614. https:\/\/doi.org\/10.1161\/ATVBAHA.114.302818 (2014).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"issue":"8","key":"22916_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1161\/01.RES.0000246086.93555.F3","volume":"99","author":"W Baldwin","year":"2006","unstructured":"Baldwin, W. et al. Allograft vasculopathy versus atherosclerosis. Circ. Res. 99 (8), 801\u2013815. https:\/\/doi.org\/10.1161\/01.RES.0000246086.93555.F3 (2006).","journal-title":"Circ. Res."},{"issue":"9","key":"22916_CR4","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1016\/J.TRANSPROCEED.2008.08.115","volume":"40","author":"IJS L\u00e1zaro","year":"2008","unstructured":"L\u00e1zaroIJS et al. Influence of traditional cardiovascular risk factors in the recipient on the development of cardiac allograft vasculopathy after heart transplantation. Transpl. Proc. 40 (9), 3056\u20133057. https:\/\/doi.org\/10.1016\/J.TRANSPROCEED.2008.08.115 (2008).","journal-title":"Transpl. Proc."},{"key":"22916_CR5","doi-asserted-by":"publisher","unstructured":"Vallakati, A., Reddy, S., Dunlap, M. E. & Taylor, D. O. Impact of Statin use after heart transplantation. Circ. Heart Fail. 9 (10). https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.116.003265\/-\/DC1 (2016).","DOI":"10.1161\/CIRCHEARTFAILURE.116.003265\/-\/DC1"},{"key":"22916_CR6","doi-asserted-by":"publisher","unstructured":"Karatasakis, A. et al. Effect of PCSK9 inhibitors on clinical outcomes in patients with hypercholesterolemia: A Meta-Analysis of 35 randomized controlled trials. J. Am. Heart Assoc. 6 (12). https:\/\/doi.org\/10.1161\/JAHA.117.006910 (2017).","DOI":"10.1161\/JAHA.117.006910"},{"issue":"4","key":"22916_CR7","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1016\/J.HEALUN.2019.01.520","volume":"38","author":"K Uyanik-Uenal","year":"2019","unstructured":"Uyanik-Uenal, K. et al. Treatment of Therapy-Resistant hyperlipidaemia after heart transplant with PCSK9-Inhibitors. J. Heart Lung Transplantation. 38 (4), S213\u2013S214. https:\/\/doi.org\/10.1016\/J.HEALUN.2019.01.520 (2019).","journal-title":"J. Heart Lung Transplantation"},{"issue":"7","key":"22916_CR8","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/J.CARDFAIL.2021.02.018","volume":"27","author":"Y Sammour","year":"2021","unstructured":"Sammour, Y. et al. PCSK9 inhibitors in heart transplant patients: Safety, Efficacy, and angiographic correlates. J. Card Fail. 27 (7), 812\u2013815. https:\/\/doi.org\/10.1016\/J.CARDFAIL.2021.02.018 (2021).","journal-title":"J. Card Fail."},{"issue":"5","key":"22916_CR9","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/J.JACL.2019.06.010","volume":"13","author":"PB Sandesara","year":"2019","unstructured":"Sandesara, P. B. et al. PCSK9 Inhibition in patients with heart transplantation: A case series. J. Clin. Lipidol. 13 (5), 721\u2013724. https:\/\/doi.org\/10.1016\/J.JACL.2019.06.010 (2019).","journal-title":"J. Clin. Lipidol."},{"key":"22916_CR10","doi-asserted-by":"publisher","unstructured":"Jennings, D. L., Jackson, R. & Farr, M. PCSK9 inhibitor use in heart transplant recipients: A case series and review of the literature. Transplantation. Published online 2020:E38-E39. https:\/\/doi.org\/10.1097\/TP.0000000000002944","DOI":"10.1097\/TP.0000000000002944"},{"issue":"1","key":"22916_CR11","first-page":"104e","volume":"35","author":"Y Moayedi","year":"2019","unstructured":"Moayedi, Y. et al. Safety and efficacy of PCSK9 inhibitors after heart transplantation. Can. J. Cardiol. 35 (1), 104e. 1-104.e3 (2019).","journal-title":"Can. J. Cardiol."},{"key":"22916_CR12","doi-asserted-by":"crossref","unstructured":"Broch, K. et al. Randomized Trial of Cholesterol Lowering With Evolocumab for Cardiac Allograft Vasculopathy in Heart Transplant Recipients. JACC Heart Fail. Published online October 1, (2024). https:\/\/doi.org\/10.1016\/J.JCHF.2024.04.026;SUBPAGE:STRING:ABSTRACT;REQUESTEDJOURNAL:JOURNAL:JCHF;WEBSITE:WEBSITE:ACCPUBS;PAGEGROUP:STRING:PUBLICATION.","DOI":"10.1016\/j.jchf.2024.04.026"},{"issue":"10","key":"22916_CR13","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/J.JCHF.2024.04.026\/SUPPL_FILE\/MMC1.DOCX","volume":"12","author":"K Broch","year":"2024","unstructured":"Broch, K. et al. Randomized trial of cholesterol Lowering with Evolocumab for cardiac allograft vasculopathy in heart transplant recipients. JACC Heart Fail. 12 (10), 1677\u20131688. https:\/\/doi.org\/10.1016\/J.JCHF.2024.04.026\/SUPPL_FILE\/MMC1.DOCX (2024).","journal-title":"JACC Heart Fail."},{"key":"22916_CR14","unstructured":"Overview | Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia | Guidance | NICE."},{"key":"22916_CR15","unstructured":"Keren, A. et al. Heart transplant rejection monitored by signal-averaged electrocardiography in patients receiving cyclosporine. Circulation. ;70(3 Pt 2):I124-9. Accessed June 4, 2023. (1984). https:\/\/europepmc.org\/article\/med\/6378424"},{"key":"22916_CR16","doi-asserted-by":"publisher","unstructured":"Noack, F. et al. The current LDL-C target\u2009<\u20091.4mmol\/l of the ESC is achieved in less than 16% of patients with coronary heart disease despite effective lipid-lowering therapy: data from the LLT-R registry. Eur. Heart J. 41 (Supplement_2). https:\/\/doi.org\/10.1093\/EHJCI\/EHAA946.2998 (2020).","DOI":"10.1093\/EHJCI\/EHAA946.2998"},{"issue":"1","key":"22916_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/EURHEARTJ\/EHZ455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach, F. et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular riskthe task force for the management of dyslipidaemias of the European society of cardiology (ESC) and European atherosclerosis society (EAS). Eur. Heart J. 41 (1), 111\u2013188. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHZ455 (2020).","journal-title":"Eur. Heart J."},{"key":"22916_CR18","doi-asserted-by":"publisher","unstructured":"Guddeti, R. R. et al. Ischemic cardiomyopathy is associated with coronary plaque progression and higher event rate in patients after cardiac transplantation. J. Am. Heart Assoc. 3 (4). https:\/\/doi.org\/10.1161\/JAHA.114.001091\/ASSET\/F8A7B05A-6443-4D76-BF72-0A499B15E3DD\/ASSETS\/IMAGES\/LARGE\/JAH3634-FIG-0004.JPG (2014).","DOI":"10.1161\/JAHA.114.001091\/ASSET\/F8A7B05A-6443-4D76-BF72-0A499B15E3DD\/ASSETS\/IMAGES\/LARGE\/JAH3634-FIG-0004.JPG"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22916-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22916-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22916-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:34:12Z","timestamp":1760427252000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22916-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22916"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22916-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"3 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None relevant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Not needed. The audit was prospectively registered with out trust audit and quality improvement system.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical"}}],"article-number":"35755"}}